Vendor, Houston, TX
Accel Diagnostics, LLC
UEI QUJ4EFCK59N4, CAGE 5G0E4
1 award and $0 obligated between February 14, 2024 and February 14, 2024, 100% under full and open competition, against 3.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N92019C00002Definitive Contract, February 14, 2024, Full and Open Competition After Exclusion of Sources, 3 offers | National Institutes of Health NhlbiNational Institutes of Health | SBIR Topic 97 - Phase II - Minimally Invasive Test for Chemotherapy-Induced Cardiotoxicity.NAICS 541715, PSC AN12 | $0 |
- Places of performance
- Texas
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards